The IPO Buzz: Zenas BioPharma (ZBIO Proposed) Sets Terms & Launches $200 Million IPO
Zenas BioPharma (ZBIO Proposed), a Phase 2/Phase 3 clinical biotech focused on MS and other autoimmune diseases, disclosed the terms for its $199.9 million IPO and launched the deal early today – Friday, Sept. 6, 2024 – for pricing next week. The clinical biotech is offering 11.8 million shares at a price range of $16.00 […]
September 6, 2024 Read More